Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase III drugs for Systemic Sclerosis (Scleroderma) ...

The use of valaciclovir as prophylaxis prevents herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE) receiving anifrolumab treatment, with no cases of zoster reported during the ...

Opens in a new tab or window The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo ...

Background: Anifrolumab, a human IgG1κ monoclonal antibody that blocks signaling from the type I interferon (IFN) receptor, is approved and recommended for the treatment of adult patients with ...

Defense mechanisms are rooted in Freud’s theory of personality.According to his model, the mind has three dueling forces: the id (unconscious and primitive urges for food, comfort, and sex), the ...

Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Polymyositis. According to GlobalData, Phase III drugs for Polymyositis does not have sufficient historical data ...

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...

While BM PC bind type I IFN receptor-blocking antibody anifrolumab, it is to a lesser degree than circulating B cells. Anti-nuclear autoantibodies (ANA) are found in the BM supernatant and PBL serum ...

The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo) from having herpes zoster ...

Reaction formation is a defense mechanism in which people express the opposite of their true feelings, sometimes to an exaggerated extent. For instance, a man who feels insecure about his ...

The decision to add valaciclovir was made at the discretion of the physician and the patient. We included 132 patients (92% of women), with a mean (SD) age of 42.0 (12.4) years treated with ...

New research identifies key cellular mechanism driving Alzheimer's disease. ScienceDaily . Retrieved January 20, 2025 from www.sciencedaily.com / releases / 2024 / 12 / 241223135051.htm ...